These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 37626929)

  • 1. Antisense Therapy for Infectious Diseases.
    Buthelezi LA; Pillay S; Ntuli NN; Gcanga L; Guler R
    Cells; 2023 Aug; 12(16):. PubMed ID: 37626929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides: a promising therapeutic option against infectious diseases.
    Tekintaş Y; Temel A
    Nucleosides Nucleotides Nucleic Acids; 2024; 43(1):1-39. PubMed ID: 37395450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense technology: an overview and prospectus.
    Crooke ST; Baker BF; Crooke RM; Liang XH
    Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in therapeutic bacterial antisense biotechnology.
    Hegarty JP; Stewart DB
    Appl Microbiol Biotechnol; 2018 Feb; 102(3):1055-1065. PubMed ID: 29209794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases.
    Schoch KM; Miller TM
    Neuron; 2017 Jun; 94(6):1056-1070. PubMed ID: 28641106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nano-bioconjugate modified with anti-SIRPα antibodies and antisense oligonucleotides of mTOR for anti-atherosclerosis therapy.
    Liu Y; Huang Q; He M; Chen T; Chu X
    Acta Biomater; 2024 Mar; 176():356-366. PubMed ID: 38160854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.
    Karaosmanoglu B; Imren G; Utine E; Taylan Sekeroglu H; Taskiran EZ
    Exp Eye Res; 2024 Apr; 241():109833. PubMed ID: 38369231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
    Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
    Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Sang A; Zhuo S; Bochanis A; Manautou JE; Bahal R; Zhong XB; Rasmussen TP
    BioDrugs; 2024 Jul; 38(4):511-526. PubMed ID: 38914784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.
    Quemener AM; Centomo ML; Sax SL; Panella R
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.
    Batista-Duharte A; Sendra L; Herrero MJ; Téllez-Martínez D; Carlos IZ; Aliño SF
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32079263
    [No Abstract]   [Full Text] [Related]  

  • 14. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases.
    Pandey M; Ojha D; Bansal S; Rode AB; Chawla G
    Mol Aspects Med; 2021 Oct; 81():101003. PubMed ID: 34332771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
    Chen S; Heendeniya SN; Le BT; Rahimizadeh K; Rabiee N; Zahra QUA; Veedu RN
    BioDrugs; 2024 Mar; 38(2):177-203. PubMed ID: 38252341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
    Barresi V; Musmeci C; Rinaldi A; Condorelli DF
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies.
    McClorey G; Wood MJ
    Curr Opin Pharmacol; 2015 Oct; 24():52-8. PubMed ID: 26277332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
    Cantara S; Simoncelli G; Ricci C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.